Our website is made possible by displaying non-intrusive online advertisements to our visitors.
Please consider supporting us by disabling or pausing your ad blocker.
This is the only gem which haven’t move yet after the bank rised mostly to their high point now. Constructions shares is moving already. So next will be this sector. Im expecting at least 30% above in returns. Just my 2cents opinion, no buy sell call
Volumn accumulation if high enough will be able to sustain beyond 5 and above. It will happen and you wont be able to chase it when the engine starts. Riding on the Golden Dragon.
Thats what we know but some are panic retailers only know how the share price like but not how the company will grow in next QR… hope it will cross 5 in March.
Very good example like CIMB, from 3.00-6.40 in 3-4 years time. Fantastic return in terms of share price and also dividend payout
Congratulations for those who have collected or top up recently. It seems that your patience will beared fruits in the near future… I have confident in this group… It will burst 5 and go to 6 beyond… another cimb in the making
Yes Leong. Past few days since Singapore and Malaysia Genting announced QR, they have been pressing down the price to maximum and eat a lot of retailers. Coz they know something is brewing behind the Life Science progress.. Now they have enough bullet to hit beyond the 52weeks high.
I believe if March 7 annoucement is promising, sky will be the limit.
I believe the drug might not be as promising as we assumed. If FDA really have intention to approve the drug, insider have definitely fly the price already. But nothing is impossible but just not over optimistic on the drug. By looking at Genting sales improvements, the TP can still be as high as 6.5
doesn't work like that for drugs development and regulatory approvals, baymax :) It's not FDA intention but rather TauRx's intention. It is TauRx's job to provide clinical trials data to the FDA for review and approvals in order to be able to proceed to the next step as much as the US market is concerned.
on the flip side, it is not uncommon to see listed pharmaceutical company's share price to spike high every time new drugs make good progress in clinical trials / when it is approved for public use which starts in phase 4; post marketing surveillance if you will. Sometimes you may see development and approvals being prioritised such as the COVID vaccine. So, it is not surprising that traders/fund managers/institutions may place "bets" for positive progress of HMTM - TauRx/Genting in this case.
Thanks, Baymax. Lol, Nick. Not a backside scheme but a prospect that should be watched closely when the clock starts ticking - when TauRx officially submitted the data to regulators.
approval is ok. the challenge is bcos of the "technical failures" in the clinical trials. TauRx is still trying hard which is a good thing. Using an alternative data analysis approach. When TauRx submits the data to regulators, it will be interesting to see whether it will be accepted as there is no placebo data.
Q4'23 performance for Genting was not well accepted. Q2'24 perhaps will not be accepted well too judging from the numbers reported by Genting Singapore plus the headwinds in the particular quarter for both Genting Singapore and GenM. Hence, the need to manage your positions well while waiting for TauRx to officially submit its data to the regulators. Nothing is submitted or planned for review by US FDA Center for Drug Evaluation and Research at the moment; at least not in the agenda for the meetings planned first half of this year.
Penetrated 52-weeks high.. Congratulations Genting fans and shareholders on successfully bringing it to the new heights. Hold on to your vote and the TP remains intact. Today TP 5%
Yes. I know. But sometimes a lot of things we will never knows… the possibility of impossible ha.ha.. follow the wind and you’ll be safe.. this time, missed the boat…
